Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Sands Cancer Center — Canandiaqua, New York
- Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in New York: - Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
- Glens Falls Hospital — Glens Falls, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Guthrie Cortland Memorial Hospital — Cortland, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Mount Sinai Hospital — New York, New York
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in New York: - MSK Commack — Commack, New York
- MSKCC-Westchester (500 Westchester Ave.) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (IDS Pharmacy) — Long Island City, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC). — New York, New York
- Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in New York: - Associated Medical Professionals - Urology ( Site 0081) — Syracuse, New York
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in New York: - Icahn School of Medicine at Mount Sinai ( Site 0009) — New York, New York
- Great Lakes Cancer Care ( Site 0047) — Williamsville, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in New York: - NYU Langone Hospitals — Brooklyn, New York
- NYU Langone Hospital Long Island — Mineola, New York
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center — New York, New York
- Columbia University Medical Center — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in New York: - Montefiore Medical Center - Medical Park — The Bronx, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in New York: - James J. Peters VA Medical Center ( Site 0088) — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in New York: - Research Site — New York, New York
- Research Site — Syracuse, New York
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in New York: - Mount Sinai Doctors Urology Faculty Practice — New York, New York
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in New York: - Research Site — New Hyde Park, New York
- Research Site — New York, New York
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in New York: - VA NY Harbor Healthcare System, New York, NY — New York, New York
Phase 3 Recruiting Academic/Other
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07548164
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) — Harrison, New York
- Weill Cornell Medical Center (Data Collection Only) — New York, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities) — Uniondale, New York
Phase 3 Recruiting Academic/Other
The purpose of this study is to look whether using local anesthesia during a transperineal prostate biopsy, while put to sleep by IV sedation, helps reduce the number of people who feel significant pain in the recovery room. The researcher…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06986083
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Consent only) — Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York
Phase 3 Recruiting Academic/Other
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radia…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06274047
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2, Phase 3 Recruiting Academic/Other
To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery afte…
Sponsor: John Elfar
NCT ID: NCT03701581
Sites in New York: - University of Rochester — Rochester, New York
Phase 3 Recruiting Academic/Other
Robotic-assisted radical prostatectomy (RALP) has become the standard of care in the management of localized prostate cancer. However, post-prostatectomy erectile dysfunction (ED) and urinary incontinence still pose a challenge that advers…
Sponsor: Icahn School of Medicine at Mount Sinai
NCT ID: NCT06945315
Sites in New York: - Mount Sinai Hospital — New York, New York
Phase 3 Recruiting Academic/Other
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (…
Sponsor: Roswell Park Cancer Institute
NCT ID: NCT06563388
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in New York: - Site US10024 — Garden City, New York
- Site US10055 — New York, New York
- Site US10059 — New York, New York
- Hudson Valley Urology, PC — Poughkeepsie, New York
- Site US10053 — Syracuse, New York
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04071236
Sites in New York: - Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in New York: - Columbia University — New York, New York
- Memorial Sloan Kettering — New York, New York